Tirofiban treatment for patients with high-risk cerebrovascular events

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter, double-blind, double-dummy, randomized clinical trial evaluates the efficacy and safety of tirofiban compared to a placebo in preventing recurrent strokes in patients with intracranial artery stenosis and high-risk acute non-disabling cerebrovascular events. Participants aged 40 and older will receive either tirofiban or placebo within 24 hours of symptom onset. The primary outcome measures include the occurrence of new ischemic strokes at three months and safety assessments based on bleeding events. The study aims to provide insights into the potential benefits of tirofiban in this specific patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria

1. 40 years or older than 40 years;
2. Acute cerebral ischemic event due to:

   * Acute non-disabling ischemic stroke (NIHSS≤5 at the time of randomization) or,
   * TIA with moderate-to-high risk of stroke (ABCD2 score ≥ 6 at the time of randomization);
3. Accompanied with symptomatic intracranial artery stenosis, defined as ≥ 50% stenosis of the infarcted ipsilateral intracranial artery. Intracranial arteries include intracranial segments of internal carotid arteries, intracranial segments of vertebral arteries, M1-M2 segments of middle cerebral arteries, A1-A2 segments of anterior cerebral arteries, P1-P2 segments of posterior cerebral arteries, and basilar artery. The techniques for detecting intracranial artery stenosis are limited to: MRA, CTA, or DSA. The measurement for the degree of stenosis has been established by the WASID (Warfarin-Aspirin Symptomatic Intracranial Disease) study. (AJNR Am J Neuroradiol. 2000;21:643-646.);
4. Can be treated with study drug within 24 hours of symptoms onset\*(\*Symptom onset is defined by the "last seen normal" principle);
5. Informed consent signed.

Exclusion Criteria

1. Malformation, tumor, abscess or other major non-ischemic brain disease (e.g., multiple sclerosis) on baseline head CT or MRI.
2. Unable to complete the evaluation of intracranial artery stenosis before randomization.
3. Isolated or pure sensory symptoms (e.g., numbness), isolated visual changes, or isolated dizziness/vertigo without evidence of acute infarction on baseline head CT or MRI.
4. Iatrogenic causes (angioplasty or surgery) of minor stroke or TIA.
5. A score of \> 2 on the modified Rankin scale before the symptom onset.
6. Contraindication for tirofiban:

   * Known allergy
   * Severe renal (creatinine exceeding 1.5 times of the upper limit of normal range) or hepatic (ALT or AST \> twice the upper limit of normal range) insufficiency
   * Severe cardiac failure (NYHA level: III to IV)
   * History of hemostatic disorder or systemic bleeding
   * History of thrombocytopenia or neutropenia
   * History of drug-induced hematologic disorder or hepatic dysfunction
   * Low white blood cell (\<2×109/L) or platelet count (\<100×109/L)
7. Tirofiban has been used since this onset.
8. Hematocrit (HCT) \<30%.
9. Clear indication for anticoagulation (presumed cardiac source of embolus, e.g., atrial fibrillation, prosthetic cardiac valves known or suspected endocarditis).
10. History of intracranial hemorrhage or amyloid angiopathy.
11. History of aneurysm (including intracranial aneurysm and peripheral aneurysm).
12. History of asthma or COPD (chronic obstructive pulmonary disease).
13. High-risk for bradyarrhythmia (sinus node disease, first-degree or second-degree AV block, and brady-arrhythmic syncope without pacemaker).
14. Planned or likely revascularization (any angioplasty or endovascular surgery) within the next 3 months.
15. Scheduled for surgery or interventional treatment requiring study drug cessation.
16. Severe non-cardiovascular comorbidity with life expectancy \< 3 months.
17. Inability to understand and/or follow research procedures due to mental, cognitive, or emotional disorders.
18. Current treatment (last dose given within 10 days before randomization) with heparin therapy or oral anti coagulation.
19. Intravenous thrombolytic therapy (such as intravenous rtPA) or mechanical thrombectomy within 24 hours prior to randomization.
20. Participants who have large areas (greater than half of middle cerebral artery territory) of obvious low density on the baseline CT scan.
21. Gastrointestinal bleed within 3 months or major surgery within 30 days.
22. Diagnosis or suspicious diagnosis of acute coronary syndrome.
23. Participation in another clinical study with an experimental product during the last 30 days.
24. Currently receiving an experimental drug or device.
25. Pregnant, currently trying to become pregnant, or of child-bearing potential and not using birth control.

Where it's running

• The 2nd Affiliated Hospital of Harbin Medical University
  Harbin, Heilongjiang, China Recruiting
• People's Hospital of Qihe County
  Dezhou, Shandong, China Recruiting
• Liaocheng People's Hospital（Liaocheng Brain Hospital）
  Liaocheng, Shandong, China Recruiting
• Third People's Hospital of Liaocheng
  Liaocheng, Shandong, China Recruiting
• Yantai Penglai traditional Chinese medicine hospital
  Yantai, Shandong, China Recruiting

Study contacts

• Study coordinator: Yongjun Wang
• Email: yongjunwang@ncrcnd.org.cn
• Phone: 13911172565

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• AI-powered decision support to boost thrombolysis for ischemic stroke

  This trial tests whether an AI-assisted decision tool helps doctors give intravenous thrombolysis to eligible ischemic stroke patients within 24 hours at a primary hospital in China, compared with standard care.

  Recruiting Capital Medical University · Changsha, Hunan · NCT07785492

• Tegoprazan to prevent GI complications in ischemic stroke patients on antiplatelet therapy

  This trial tests whether tegoprazan can lower gastrointestinal complications in adults with ischemic stroke or TIA who are starting antiplatelet therapy.

  Recruiting at 24 sites Phase 3 Hanyang University · Busan, Busan and 23 other locations · NCT07687706

• Intra-arterial Thrombolysis for Acute Ischemic Stroke with Medium Vessel Occlusion

  This trial tests whether delivering a clot-busting medicine directly into the brain’s medium vessels helps improve outcomes for adults with acute ischemic stroke caused by MeVO, on top of standard care.

  Recruiting Phase 3 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07668323

• Single Bolus Non-immunogenic Staphylokinase in Acute Ischemic Stroke (4.5–24 hours)

  This trial tests a single 10 mg bolus of non-immunogenic staphylokinase versus placebo in adults with acute ischemic stroke 4.5–24 hours after onset to see if it helps restore blood flow and improve outcomes.

  Recruiting at 10 sites Phase 3 Supergene, LLC · Ryazan, Ryazan Oblast and 16 other locations · NCT07324837

• Imaging to detect impaired microcirculatory reperfusion after clot removal

  This project tests whether CT perfusion scans done after clot removal can spot poor tiny-vessel blood flow in adults with large-vessel ischemic stroke.

  Recruiting University of Cincinnati · Cincinnati, Ohio · NCT07099599

• Cerebrolysin for early rehabilitation after acute ischemic stroke

  This trial tests whether adding Cerebrolysin to standard early rehabilitation helps people with moderate acute ischemic stroke recover arm and overall function faster.

  Recruiting University Medical Centre Ljubljana · Ljubljana · NCT07043686

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.